Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Next Phase In Oncology: FDA’s Pazdur On “Breakthrough” Drug Development

This article was originally published in RPM Report

Executive Summary

At a small press briefing on personalized medicine, FDA’s top cancer drug reviewer paints a picture of the next phase in cancer drug development.

You may also be interested in...

The Impact of Iclusig: Access Program May Have Important Implications For Personalized Medicine

FDA’s decision to seek the withdrawal of Ariad’s Iclusig prompted concerns about greater caution by the agency in the “Breakthrough” era. A more important implication, however, may be in whether the continued access program succeeds in meeting demand for the product. That could become a model for future development of ever-more personalized cancer treatment regimens.

“Breakthrough Therapy”: New Pathway in FDASIA May Point The Way To Future Reforms

A new FDA designation process for “breakthrough” drugs is one of the few “innovation” features of the FDA Safety & Innovation Act. It is likely to be very attractive to biotech sponsors, though its impact on actual product approvals is uncertain at best. The real “breakthrough,” though, may be in the collaborative model that led to the legislation – and that is an important message for sponsors hoping for bigger reforms ahead.

Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies

When Richard Pazdur discussed ideas for a National Cancer Policy at an IoM event, one theme was unmistakable: if sponsors really believe what they say about targeted therapies for cancer, they should aim high with their clinical trial designs and endpoints.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts